Drug intelligence / Profile preview

R7027

Development stage: Preclinical
Lead developer: Harbour BioMed
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

R7027 is a preclinical-stage bispecific antibody candidate being developed by Harbour BioMed (HBMK) for the treatment of autoimmune diseases. Developed using the company's proprietary antibody discovery platforms, R7027 is engineered to simultaneously bind two distinct targets to achieve synergistic therapeutic effects in immune-mediated inflammatory conditions. As of early 2024, the specific molecular targets of R7027 remain undisclosed by the developer, but the asset is a key part of Harbour BioMed's immunology and inflammation pipeline.

Targets

BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on R7027.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R7027.

Explore the full profile